Publication | Open Access

P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel

OncologyHealth SciencesP-glycoprotein InhibitionMedicineAntitumor EfficacyPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchDrug Resistance